Skip to main content

Bemcentinib in Treating Patients with Recurrent Glioblastoma Undergoing Surgery

Trial Status: Active

This phase I trial studies how well bemcentinib works in treating patients with glioblastoma that has come back who are undergoing surgery. Bemcentinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Inclusion Criteria

  • Patients must have histologically confirmed glioblastoma (GBM) that is progressive or recurrent following radiation therapy +/- chemotherapy. Patients with previous low-grade glioma who progressed after radiation therapy (RT)/chemotherapy and are biopsied and found to have GBM/gliosarcoma (GS) are eligible
  • Patients must have measurable, supratentorial contrast-enhancing progressive or recurrent glioblastoma or gliosarcoma by magnetic resonance imaging (MRI) within 21 days of starting treatment. Patient must be able to tolerate MRIs
  • Patients may have had treatment for no more than 2 prior relapses
  • Patients must have a tumor tissue form indicating availability of archived tissue from initial resection at diagnosis of GBM or GS, completed and signed by a pathologist. Sites must agree to provide this form within 14 days after treatment start. Availability of tissue is not a requirement for study participation
  • The following intervals from previous treatments are required to be eligible: * 12 weeks from the completion of radiation * 6 weeks from a nitrosourea chemotherapy or mitomycin C * 3 weeks from a non-nitrosourea chemotherapy * 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents * 2 weeks from administration of a non-cytotoxic, FDA-approved agent, e.g., erlotinib, hydroxychloroquine, etc.) * 4 weeks from prior antiangiogenesis therapy (approved or investigational) (e.g., bevacizumab, aflibercept, ramucirumab, cediranib, cabozantinib, etc.) * 4 weeks from any immunotherapy intervention
  • Patients must be undergoing surgery that is clinically indicated as determined by their care providers. Patients must be eligible for surgical resection according to the following criteria: * Expectation that the surgeon is able to resect 0.05-0.10 cm^3 (50-100 mg) of tumor from enhancing tumor and at least 0.05-0.10 cm^3 (50-100 mg) from non-enhancing tumor with low risk of inducing neurological injury
  • Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
  • Absolute neutrophil count >= 1,500/uL
  • Platelets >= 100,000/uL
  • Hemoglobin >= 9 g/dL
  • Total bilirubin < 1.5 x upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x institutional upper limit of normal
  • Creatinine =< 1.5 x institutional upper limit of normal AND creatinine clearance >= 60 ml/min/1.73m^2 for patients with creatinine levels above institutional normal.
  • Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
  • Patients must have a 12-lead electrocardiogram with a measurable corrected QT using Fridericia's correction formula (QTcF) =< 450 msec
  • Patients must be able to provide written informed consent
  • Women of childbearing potential must have a negative serum pregnancy test prior to study entry. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and through 4 months after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of bemcentinib administration
  • Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder. Patients with prior malignancies must be disease-free for >= five years
  • Patients must be able to swallow whole capsules

Exclusion Criteria

  • Patients receiving any other investigational agents during or within 4 weeks of the first dose of study therapy are ineligible.
  • Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bemcentinib are ineligible. The investigator brochure can be referenced for more information.
  • Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol. Patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs. Patients previously treated with an EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to treatment start
  • Patients with a history of bleeding diathesis are ineligible
  • Patients who have not recovered to < Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicities related to prior therapy are ineligible
  • Patients considered at risk of QTc induced arrhythmias or uncontrolled or significant cardiovascular disease, including, but not limited to, any of the following are ineligible: * Abnormal left ventricular ejection fraction on echocardiography (less than the lower limit of normal for a subject of that age at the treating institution or < 45%) * History of an ischemic cardiac event including myocardial infarction within 3 months of study entry * Congestive cardiac failure of > grade 2 severity according to the New York Heart Association as defined by symptomatic at less than ordinary levels of activity * Unstable cardiac disease including unstable angina or hypertension as defined by the need for change in medication within the last 3 months * History or presence of bradycardia (=< 60 beats per minute [bpm]) or history of symptomatic bradycardia, left bundle branch block, cardiac pacemaker or significant atrial tachyarrhythmias as defined by the need for treatment * Current treatment with any agent known to cause torsade de points which cannot be discontinued at least two weeks prior to treatment * Known family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy * Previous history of drug-induced QTc prolongation * Screening 12-lead electrocardiogram (ECG) with a measurable QTcF > 450 ms
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible
  • Pregnant women are excluded from this study because the effects of bemcentinib on a fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with bemcentinib, breastfeeding should be discontinued if the mother is treated with bemcentinib.
  • Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: * A stable regimen of highly active anti-retroviral therapy (HAART) not containing a strong inducer or inhibitor of CYP2C9 * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections * A CD4 count above 250 cells/uL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
  • Patients with existing gastrointestinal disease affecting drug absorption such as celiac disease or Crohn’s disease, or previous bowel resection which is considered to be clinically significant or could interfere with absorption are ineligible.
  • Patients with known lactose intolerance are ineligible.
  • Patients with known active infection with hepatitis B or C viruses (screening not required, follow institutional practice): * Patients who have a history of hepatitis B infection are eligible provided they are hepatitis B surface antigen negative. * Patients who have a history of hepatitis C infection are eligible provided they have no evidence of hepatitis C ribonucleic acid using a quantitative polymerase chain reaction assay at least 6 months after completing treatment for hepatitis C infection.
  • Patients who have major surgery within 4 weeks prior to date of enrollment are ineligible, excluding skin biopsies and procedures for insertion of central venous access devices.
  • Patients who have had treatment with any of the following are ineligible: histamine receptor 2 inhibitors, proton pump inhibitors or antacids within 7 days of start of treatment.


University of Alabama at Birmingham Cancer Center
Status: ACTIVE
Contact: Site Public Contact
Phone: 205-934-0220


Henry Ford Hospital
Status: ACTIVE
Contact: Site Public Contact
Phone: 313-916-3721

North Carolina

Wake Forest University Health Sciences
Status: ACTIVE
Contact: Site Public Contact
Phone: 336-713-6771


I. Evaluate the penetration of bemcentinib across the blood brain barrier measured by pharmacokinetics/drug concentration of 1.0 uM in tissue resected from a contrast enhancing region of the tumor in 60% of recurrent glioblastoma patients.


I. Determine AXL expression, phosphorylation state (AXL phosphospecific antibody if AXL is inhibited), and circulating soluble AXL levels.

II. Determine the bemcentinib concentration in tissue resected from a contrast non-enhancing region of the tumor.

III. Characterize the steady state pharmacokinetics of bemcentinib in patients with recurrent glioblastoma.

IV. Estimate safety and tolerability of bemcentinib for recurrent glioblastoma.

V. Assess the progression-free and overall survival of patients with recurrent glioblastoma.

OUTLINE: Patients are assigned to 1 of 2 groups.

GROUP A: Patients receive bemcentinib orally (PO) once daily (QD) on days 1-5 days, then undergo surgery 3-6 hours after last dose. Within 45 days, patients receive bemcentinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

GROUP B: Patients undergo surgery, then within 45 days receive bemcentinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, then every 2 months for the first 2 years, then every 6 months thereafter.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Adult Brain Tumor Consortium

Principal Investigator
Ichiro Nakano

  • Primary ID ABTC-1701
  • Secondary IDs NCI-2018-01562
  • ID NCT03965494